Office for National Statistics. Cancer registration statistics, England: 2014 2016 [Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/2014.
Eurostat. Cancer statistics - specific cancers. 2017.
Cancer Research UK. Lung cancer survival statistics. 2017.
National Lung Screening Trial Research Team, Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368(21):1980–91.
Field JK, Duffy SW, Baldwin DR, Brain KE, Devaraj A, Eisen T, et al. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess. 2016;20(40):1–146.
Field JK, Duffy SW, Baldwin DR, Whynes DK, Devaraj A, Brain KE, et al. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax. 2016;71(2):161.
Whynes DK. Could CT screening for lung cancer ever be cost effective in the United Kingdom? Cost Eff Resour Alloc. 2008;6(1):5.
Black WC. Computed tomography screening for lung cancer in the National Lung Screening Trial: a cost-effectiveness analysis. J Thorac Imaging. 2015;30(2):79–87.
Black WC, Gareen IF, Soneji SS, Sicks JD, Keeler EB, Aberle DR, et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2014;371(19):1793–802.
Hinde S, Crilly T, Balata H, Bartlett R, Crilly J, Barber P, et al. The cost-effectiveness of the Manchester ‘lung health checks’, a community-based lung cancer low-dose CT screening pilot. Lung Cancer. 2018;126:119–24.
McMahon PM, Kong CY, Bouzan C, Weinstein MC, Cipriano LE, Tramontano AC, et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol. 2011;6(11):1841–8.
Goffin JR, Flanagan WM, Miller AB, Fitzgerald NR, Memon S, Wolfson MC, et al. Cost-effectiveness of lung cancer screening in Canada. JAMA Oncol. 2015;1(6):807–13.
Goffin JR, Flanagan WM, Miller AB, Fitzgerald NR, Memon S, Wolfson MC, et al. Biennial lung cancer screening in Canada with smoking cessation—outcomes and cost-effectiveness. Lung Cancer. 2016;101:98–103.
ten Haaf K, Tammemägi MC, Bondy SJ, van der Aalst CM, Gu S, McGregor SE, et al. Performance and cost-effectiveness of computed tomography lung cancer screening scenarios in a population-based setting: a microsimulation modeling analysis in Ontario, Canada. PLoS Med. 2017;14(2):e1002225.
Snowsill T, Yang H, Griffin E, Long L, Varley-Campbell J, Coelho H, et al. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation. Health Technol Assess. 2018;22(69):1–276.
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231–50.
Moyer VA. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330–8.
Cassidy A, Myles JP, van Tongeren M, Page RD, Liloglou T, Duffy SW, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer. 2008;98(2):270–6.
Field JKDS, Baldwin DR, et al. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess. 2016;20(40):Appendix 2 Details of the Liverpool Lung Project risk model (version).
Clark MA, Gorelick JJ, Sicks JD, Park ER, Graham AL, Abrams DB, et al. The relations between false positive and negative screens and smoking cessation and relapse in the National Lung Screening Trial: implications for public health. Nicotine Tob Res. 2016;18(1):17–24.
Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14.
Office for National Statistics. Interim life tables: England and Wales, 2010-2012 2013 [cited 2017 June 21]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/bulletins/interimlifetables/englandandwales20102012.
Continuous Mortality Investigation Mortality Committee. Working paper 21 - The graduation of the CMI 1999-2002 mortality experience: final “00” series mortality tables - assured lives. London: Institute and Faculty of Actuaries; 2006.
Office for National Statistics. Deaths registered in England and Wales, 2014: Table 5.2 Neoplasms 2015 [Available from: https://www.ons.gov.uk/file?uri=/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathsregisteredinenglandandwalesseriesdrreferencetables/2014table5/table5causeofdeath_tcm77-422538.xls.
Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368(21):1980–91.
Health & Social Care Information Centre. Statistics on smoking: England, 2016 2016 [Available from: http://content.digital.nhs.uk/catalogue/PUB20781/stat-smok-eng-2016-tab.xlsx.
Craig R, Mindell J. Health Survey for England 2014: Health, social care and lifestyles. Summary of key findings. Leeds: The Health and Social Care Information Centre; 2014.
Tramontano AC, Schrag DL, Malin JK, Miller MC, Weeks JC, Swan JS, et al. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study. Med Decis Mak. 2015;35(3):371–87.
van den Bergh KAM, Essink-Bot ML, Borsboom GJJM, Scholten ET, Prokop M, de Koning HJ, et al. Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON). Br J Cancer. 2010;102(1):27–34.
Mazzone PJ, Obuchowski N, Fu AZ, Phillips M, Meziane M. Quality of life and healthcare use in a randomized controlled lung cancer screening study. Ann Am Thorac Soc. 2013;10(4):324–9.
Department of Health. NHS reference costs 2015 to 2016. 2016.
Curtis L, Burns A. Unit costs of health and social care 2016. Canterbury: Personal Social Services Research Unit, University of Kent; 2016.
Kennedy MP, Hall PS, Callister ME. Factors affecting hospital costs in lung cancer patients in the United Kingdom. Lung Cancer. 2016;97:8–14.
McGuire A, Martin M, Lenz C, Sollano JA. Treatment cost of non-small cell lung cancer in three European countries: comparisons across France, Germany, and England using administrative databases. J Med Econ. 2015;18(7):525–32.
Round J, Jones L, Morris S. Estimating the cost of caring for people with cancer at the end of life: a modelling study. Palliat Med. 2015;29(10):899–907.
Office for National Statistics. Population estimates for the UK, England and Wales, Scotland and Northern Ireland: mid-2015. 2016.
Griffin EA, C, Snowsill, TM et al. UK lung cancer screening model: the Exeter natural history based economic model of lung cancer screening. Open research Exeter (ORE). 2018; College of Medicine and Health Institute of Health Research.
Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10(8):779–87.
National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013.
Ten Haaf K, Tammemagi MC, Bondy SJ, van der Aalst CM, Gu S, McGregor SE, et al. Performance and cost-effectiveness of computed tomography lung cancer screening scenarios in a population-based setting: a microsimulation modeling analysis in Ontario, Canada. PLoS Med. 2017;14(2):e1002225.
Patz EF Jr, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemagi MC, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014;174(2):269–74.
Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, et al. Early lung cancer action project: a summary of the findings on baseline screening. Oncologist. 2001;6(2):147–52.
Rubin GD. Lung nodule and cancer detection in CT screening. J Thorac Imaging. 2015;30(2):130–8.
Whyte S TC, Kearns B, Webster M, Chilcott J. Optimising bowel cancer screening. Phase 1: optimising the cost effectiveness of repeated FIT screening and screening strategies combining bowel scope and FIT screening. UK National Screening Committee. 2018.
Kitchener HC. Report to the National Screening Committee, cervical cancer. UK National Screening Committee. 2015.
Kearns K CJ, Whyte S, Calvert N, Preston L. An economic evaluation of the cost-effectiveness of screening for ovarian cancer amongst post-menopausal women who are not at high risk of ovarian cancer. ScHARR for the UK National Screening Committee. 2016.
Hinde S, Crilly T, Balata H, Bartlett R, Crilly J, Barber P, et al. The cost-effectiveness of the Manchester lung health checks 2019;, a community-based lung cancer low-dose CT screening pilot. Lung Cancer. 2018;126:119–24.
De Koning HJ. NELSON study shows CT screening for nodule volume management reduces lung cancer mortality by 26 percent in men. IASLC 19th World Conference on Lung Cancer Press Release. 2018.